Skip to main content

Compugen Ltd. (CGEN)

NASDAQ: CGEN · IEX Real-Time Price · USD
6.22 -0.24 (-3.72%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap537.33M
Revenue (ttm)2.00M
Net Income (ttm)-35.73M
Shares Out83.92M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume339,324
Open6.35
Previous Close6.46
Day's Range6.15 - 6.46
52-Week Range5.76 - 18.75
Beta2.31
AnalystsStrong Buy
Price Target21.33 (+243.0%)
Est. Earnings DateNov 4, 2021

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its ...

IndustryLife Sciences Tools & Services
IPO DateAug 11, 2000
Employees68
Stock ExchangeNASDAQ
Ticker SymbolCGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Compugen stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 242.98% from the latest price.

Price Target
$21.33
(242.98% upside)
Analyst Consensus: Strong Buy

News

Compugen to Present at the Cantor Global Healthcare Conference

HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd.

1 week ago - PRNewsWire

Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...

1 month ago - PRNewsWire

This Unknown Biotech Has a Secret Weapon for Outsized Returns

Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.

Other symbols:BIOTMO
1 month ago - The Motley Fool

Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial

AstraZeneca Plc's (NASDAQ: AZN) bispecific antibody derived from Compugen Ltd's (NASDAQ: CGEN) COM902 will advance into clinical development.  AstraZeneca plans to initiate a Phase 1/2 study evaluating ...

1 month ago - Benzinga

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

HOLON, Israel , Aug. 19, 2021  /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced tha...

1 month ago - PRNewsWire

Why Compugen Stock Is Rising Again Today

Momentum is carrying over from the company's second-quarter update on Wednesday.

1 month ago - The Motley Fool

Why Compugen Stock Is Jumping Today

Investors were especially interested in the company's pipeline update.

1 month ago - The Motley Fool

Compugen Reports Second Quarter 2021 Results

HOLON, Israel, July 28, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for...

1 month ago - PRNewsWire

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myer...

HOLON, Israel, July 19, 2021 /PRNewswire/ --   Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first pat...

2 months ago - PRNewsWire

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

HOLON, Israel , July 15, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first patie...

2 months ago - PRNewsWire

Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021

HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company wil...

2 months ago - PRNewsWire

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

HOLON, Israel, June 30, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patie...

2 months ago - PRNewsWire

Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

HOLON, Israel, June 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of ...

2 months ago - PRNewsWire

Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients

Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers Squib...

3 months ago - Benzinga

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Mee...

HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase ...

3 months ago - PRNewsWire

Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities

HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its s...

3 months ago - PRNewsWire

Why Compugen Stock Is Jumping Today

Investors liked what the company had to say in its Q1 update.

4 months ago - The Motley Fool

Compugen Reports First Quarter 2021 Results

HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

4 months ago - PRNewsWire

Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series

HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph.D.

4 months ago - PRNewsWire

Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Disco...

HOLON, Israel, May 10, 2021 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded...

4 months ago - PRNewsWire

Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021

HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

4 months ago - PRNewsWire

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 An...

HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will presen...

4 months ago - PRNewsWire

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

HOLON, Israel, April 27, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of ...

4 months ago - PRNewsWire

7 Stocks That Could Double by Summer

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

5 months ago - InvestorPlace

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

HOLON, Israel, March 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a...

6 months ago - PRNewsWire